Cargando…

Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators

Acute-on chronic liver failure (ACLF) is a syndrome that develops in patients with acutely decompensated cirrhosis (AD). It is characterized by a systemic hyperinflammatory state, leading to multiple organ failure. Our objective was to analyze macrophage anti-inflammatory protein CD5L in plasma extr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Rodríguez, María Belen, Téllez, Érica, Casulleras, Mireia, Borràs, Francesc E., Arroyo, Vicente, Clària, Joan, Sarrias, Maria-Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940329/
https://www.ncbi.nlm.nih.gov/pubmed/35330909
http://dx.doi.org/10.3389/fimmu.2022.842996
_version_ 1784672907376459776
author Sánchez-Rodríguez, María Belen
Téllez, Érica
Casulleras, Mireia
Borràs, Francesc E.
Arroyo, Vicente
Clària, Joan
Sarrias, Maria-Rosa
author_facet Sánchez-Rodríguez, María Belen
Téllez, Érica
Casulleras, Mireia
Borràs, Francesc E.
Arroyo, Vicente
Clària, Joan
Sarrias, Maria-Rosa
author_sort Sánchez-Rodríguez, María Belen
collection PubMed
description Acute-on chronic liver failure (ACLF) is a syndrome that develops in patients with acutely decompensated cirrhosis (AD). It is characterized by a systemic hyperinflammatory state, leading to multiple organ failure. Our objective was to analyze macrophage anti-inflammatory protein CD5L in plasma extracellular vesicles (EVs) and assess its as yet unknown relationship with lipid mediators in ACLF. With this aim, EVs were purified by size exclusion chromatography from the plasma of healthy subjects (HS) (n=6) and patients with compensated cirrhosis (CC) (n=6), AD (n=11) and ACLF (n=11), which were defined as positive for CD9, CD5L and CD63 and their size, number, morphology and lipid mediator content were characterized by NTA, EM, and LC-MS/MS, respectively. Additionally, plasma CD5L was quantified by ELISA in 10 HS, 20 CC and 149 AD patients (69 ACLF). Moreover, macrophage CD5L expression and the biosynthesis of specialized lipid mediators (SPMs) were characterized in vitro in primary cells. Our results indicate that circulating EVs were significantly suppressed in cirrhosis, regardless of severity, and showed considerable alterations in CD5L and lipid mediator content as the disease progressed. In AD, levels of EV CD5L correlated best with those of the SPM RvE1. Analysis of total plasma supported these data and showed that, in ACLF, low CD5L levels were associated with circulatory (p<0.001), brain (p<0.008) and respiratory (p<0.05) failure (Mann-Whitney test). Functional studies in macrophages indicated a positive feedback loop between CD5L and RvE1 biosynthesis. In summary, we have determined a significant alteration of circulating EV contents in ACLF, with a loss of anti-inflammatory and pro-resolving molecules involved in the control of acute inflammation in this condition.
format Online
Article
Text
id pubmed-8940329
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89403292022-03-23 Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators Sánchez-Rodríguez, María Belen Téllez, Érica Casulleras, Mireia Borràs, Francesc E. Arroyo, Vicente Clària, Joan Sarrias, Maria-Rosa Front Immunol Immunology Acute-on chronic liver failure (ACLF) is a syndrome that develops in patients with acutely decompensated cirrhosis (AD). It is characterized by a systemic hyperinflammatory state, leading to multiple organ failure. Our objective was to analyze macrophage anti-inflammatory protein CD5L in plasma extracellular vesicles (EVs) and assess its as yet unknown relationship with lipid mediators in ACLF. With this aim, EVs were purified by size exclusion chromatography from the plasma of healthy subjects (HS) (n=6) and patients with compensated cirrhosis (CC) (n=6), AD (n=11) and ACLF (n=11), which were defined as positive for CD9, CD5L and CD63 and their size, number, morphology and lipid mediator content were characterized by NTA, EM, and LC-MS/MS, respectively. Additionally, plasma CD5L was quantified by ELISA in 10 HS, 20 CC and 149 AD patients (69 ACLF). Moreover, macrophage CD5L expression and the biosynthesis of specialized lipid mediators (SPMs) were characterized in vitro in primary cells. Our results indicate that circulating EVs were significantly suppressed in cirrhosis, regardless of severity, and showed considerable alterations in CD5L and lipid mediator content as the disease progressed. In AD, levels of EV CD5L correlated best with those of the SPM RvE1. Analysis of total plasma supported these data and showed that, in ACLF, low CD5L levels were associated with circulatory (p<0.001), brain (p<0.008) and respiratory (p<0.05) failure (Mann-Whitney test). Functional studies in macrophages indicated a positive feedback loop between CD5L and RvE1 biosynthesis. In summary, we have determined a significant alteration of circulating EV contents in ACLF, with a loss of anti-inflammatory and pro-resolving molecules involved in the control of acute inflammation in this condition. Frontiers Media S.A. 2022-03-07 /pmc/articles/PMC8940329/ /pubmed/35330909 http://dx.doi.org/10.3389/fimmu.2022.842996 Text en Copyright © 2022 Sánchez-Rodríguez, Téllez, Casulleras, Borràs, Arroyo, Clària and Sarrias https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Sánchez-Rodríguez, María Belen
Téllez, Érica
Casulleras, Mireia
Borràs, Francesc E.
Arroyo, Vicente
Clària, Joan
Sarrias, Maria-Rosa
Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators
title Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators
title_full Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators
title_fullStr Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators
title_full_unstemmed Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators
title_short Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators
title_sort reduced plasma extracellular vesicle cd5l content in patients with acute-on-chronic liver failure: interplay with specialized pro-resolving lipid mediators
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940329/
https://www.ncbi.nlm.nih.gov/pubmed/35330909
http://dx.doi.org/10.3389/fimmu.2022.842996
work_keys_str_mv AT sanchezrodriguezmariabelen reducedplasmaextracellularvesiclecd5lcontentinpatientswithacuteonchronicliverfailureinterplaywithspecializedproresolvinglipidmediators
AT tellezerica reducedplasmaextracellularvesiclecd5lcontentinpatientswithacuteonchronicliverfailureinterplaywithspecializedproresolvinglipidmediators
AT casullerasmireia reducedplasmaextracellularvesiclecd5lcontentinpatientswithacuteonchronicliverfailureinterplaywithspecializedproresolvinglipidmediators
AT borrasfrancesce reducedplasmaextracellularvesiclecd5lcontentinpatientswithacuteonchronicliverfailureinterplaywithspecializedproresolvinglipidmediators
AT arroyovicente reducedplasmaextracellularvesiclecd5lcontentinpatientswithacuteonchronicliverfailureinterplaywithspecializedproresolvinglipidmediators
AT clariajoan reducedplasmaextracellularvesiclecd5lcontentinpatientswithacuteonchronicliverfailureinterplaywithspecializedproresolvinglipidmediators
AT sarriasmariarosa reducedplasmaextracellularvesiclecd5lcontentinpatientswithacuteonchronicliverfailureinterplaywithspecializedproresolvinglipidmediators